From: Validation of cellular tests for Lyme borreliosis (VICTORY) study
 | Baseline | 6 weeks | 3 months | 6 months | 9 months | 12 months |
---|---|---|---|---|---|---|
Written information and informed consent | X | Â | Â | Â | Â | Â |
Baseline characteristics | X | Â | Â | Â | Â | Â |
Physical examination | X | Â | Â | Â | Â | Â |
Recording LB manifestation, treatment and concomitant medication | X | Â | X | X | X | X |
Recording adverse events | X | Â | X | X | Â | X |
Laboratory measurements | ||||||
 B. burgdorferi s.l. serology | X |  | X |  |  |  |
 Spirofind Revised | X |  | X |  |  |  |
 QuantiFERON-LB | X |  | X |  |  |  |
 iSpot Lyme | X |  | X |  |  |  |
 LTT-MELISA | X |  | X |  |  |  |
Questionnaires | ||||||
 CIS1 (subscale fatigue), SF-36 (subscale pain), CFQ | X |  | Xa | X | Xa | X |
 Clinical parameters: PHQ-15, SF-36 (subscale physical functioning and subscale social functioning), TiC-P (health care use and absenteeism of work) | X |  | X | X | X | X |
 Cognitive-behavioral parameters: brief IPQ, CBRSQ, HADS, SES-F, PCS, IPAQ | X |  | X | X |  |  |
 Comorbidities: TiC-P (co-morbidity list) | X |  |  |  |  | X |
 Comorbidities: PREDIS | X |  |  |  |  |  |